Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Enzolytics, Inc.

Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property
Tickers ENZC
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence
Tickers ENZC
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics, Inc. Reports Progress and Future Plans
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics IPF Immune(TM) Introduced to Large and Small Retail Buyers at Recent ECRM "Weight Management, Nutrition, and Vitamin Program"
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property
Tickers ENZC
Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics, Inc. Announces New Advisory Board Member
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Intellectual Property
Tickers ENZC
Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property
Tickers ENZC
Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic
From Enzolytics, Inc.
Via AccessWire
Tickers ENZC
Enzolytics Announces Progress As It Recognizes World AIDS Day
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Tickers ENZC
Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers ENZC
Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Tickers ENZC
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Tickers ENZC
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Tickers ENZC
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Tickers ENZC
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Tickers ENZC
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Fraud Regulatory Compliance
Tickers ENZC
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Tickers ENZC
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers ENZC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.